ISLAMABAD: Although the number of antibacterial agents in the clinical pipeline increased from 80 in 2021 to 97 in 2023, there is a pressing need for new, innovative agents for serious infections and to replace those becoming ineffective due to widespread use, World Health Organization (WHO) said in its annual report Saturday.
First released in 2017, this annual report evaluates whether the current research and development (R&D) pipeline properly addresses infections caused by the drug-resistant bacteria most threatening to human health, as detailed in the 2024 WHO bacterial priority pathogen list (BPPL). Both documents aim to steer antibacterial R&D to counter better the ever-growing threat of antimicrobial resistance (AMR).
Antimicrobial Resistance (AMR) occurs when bacteria, viruses, fungi, and parasites no longer respond to medicines, making people sicker and increasing the risk of spread of infections that are difficult to treat, illness and death. AMR is driven largely by the misuse and overuse of antimicrobials, yet, at the same time, many people around the world do not have access to essential antimicrobial medicines.
“Antimicrobial resistance is only getting worse yet we’re not developing new trailblazing products fast enough to combat the most dangerous and deadly bacteria,” said Dr Yukiko Nakatani, WHO’s Assistant Director-General for Antimicrobial Resistance ad interim. “Innovation is badly lacking yet, even when new products are authorized, access is a serious challenge. Antibacterial agents are simply not reaching the patients who desperately need them, in countries of all income levels.”
Not only are there too few antibacterials in the pipeline, given how long is needed for R&D and the likelihood of failure but there is also not enough innovation. Of the 32 antibiotics under development to address BPPL infections, only 12 can be considered innovative. Furthermore, just 4 of these 12 are active against at least 1 WHO ‘critical’ pathogen – critical being the BPPL’s top risk category, over ‘high’ and ‘medium’ priority. There are gaps across the entire pipeline, including in products for children, oral formulations more convenient for outpatients, and agents to tackle rising drug resistance.
Encouragingly, non-traditional biological agents, such as bacteriophages, antibodies, anti-virulence agents, immune-modulating agents, and micro-biome-modulating agents, are increasingly being explored as complements and alternatives to antibiotics. However, studying and regulating non-traditional agents is not straightforward. Further efforts are needed to facilitate clinical studies and assessments of these products, to help determine when and how to use these agents clinically.
Looking at newly approved antibacterial, since 1 July 2017, 13 new antibiotics have obtained marketing authorization but only 2 represent a new chemical class and can be termed innovative, underscoring the scientific and technical challenge in discovering novel antibacterial that are both effective against bacteria and safe for humans.
In addition, 3 non-traditional agents have been authorized, all are faecal-based products for restoring the gut microbiota, to prevent recurrent Clostridioides Difficile Infection (CDI) following antibiotic treatment in adults.
The preclinical pipeline is active and innovative, with many non-traditional approaches, as part of a stable number of preclinical candidates over the last 4 years. Its focus remains on Gram-negative pathogens, which are resistant to last-resort antibiotics. Gram-negative bacteria have built-in abilities to find new ways to resist treatment and can pass along genetic material that allows other bacteria to become drug-resistant as well.
The shift towards antibacterial agents targeting a single pathogen appears to have plateaued. Agents targeting a single pathogen increase the need for widely available and affordably priced rapid diagnostics, to ensure the relevant bacteria are present in the infections to be treated.
Greater transparency in the pipeline would: facilitate collaboration around potentially innovative but challenging projects, help scientists and drug developers, and generate more interest and funding for drug development for novel antibacterial agents.
Efforts to develop new antibacterial agents must be accompanied by parallel efforts to ensure they can be equitably accessed, particularly in low- and middle-income countries.
Universal access to quality and affordable tools for preventing, diagnosing and treating infections is key to mitigating AMR’s impact on public health and the economy, as per WHO’s Strategic and Operational Priorities for Addressing AMR in the Human Health Sector, the AMR resolution adopted by the 77th World Health Assembly and the people-centered approach to addressing AMR and a core package of AMR interventions.
